| Gooden Mobile Pod Nc Pllc | |
|
311 Mcfadyen Dr, Fayetteville, NC 28314 | |
| (502) 244-2441 | |
| (502) 254-4069 |
| Full Name | Gooden Mobile Pod Nc Pllc |
|---|---|
| Type | Facility |
| Speciality | Podiatrist |
| Location | 311 Mcfadyen Dr, Fayetteville, North Carolina |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073003752 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | (* (Not Available)) | Primary |
| Provider Name | Milton W Richardson |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1467413419 PECOS PAC ID: 9638169345 Enrollment ID: I20040514000739 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Rhonda Michelle Cartee |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1730159864 PECOS PAC ID: 7618930553 Enrollment ID: I20041110001235 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Colin L Moffett |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1568411007 PECOS PAC ID: 4486676723 Enrollment ID: I20051229000566 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Jason C Zeigler |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1164530200 PECOS PAC ID: 7517059256 Enrollment ID: I20070824000809 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | John P Miketa |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1013138528 PECOS PAC ID: 0345275525 Enrollment ID: I20080401000791 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Jenny Lind Hall |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1528141850 PECOS PAC ID: 7012088107 Enrollment ID: I20080617000573 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | James R Shipley |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1326195504 PECOS PAC ID: 4183721095 Enrollment ID: I20080915000337 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Brian D Futrell |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1265471890 PECOS PAC ID: 0244132421 Enrollment ID: I20090923000761 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Carroll D Kratzer |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1588667265 PECOS PAC ID: 5193867034 Enrollment ID: I20100115000176 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Paul J Keane |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1194829838 PECOS PAC ID: 2668408329 Enrollment ID: I20100125000619 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | James Leroy Edwards |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1598854895 PECOS PAC ID: 9830232149 Enrollment ID: I20100209000666 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Christine R Wright |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1770544306 PECOS PAC ID: 5890870562 Enrollment ID: I20100222000351 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Laura E Durkin |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1831401371 PECOS PAC ID: 1850425489 Enrollment ID: I20100817001490 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Paul R Glaser |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1376595801 PECOS PAC ID: 2163485806 Enrollment ID: I20101216000375 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Jack M Sibrizzi |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1518247881 PECOS PAC ID: 3173796661 Enrollment ID: I20111027000971 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Christy Lynn Phillips |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1346533304 PECOS PAC ID: 6002089513 Enrollment ID: I20111028000227 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Eric Simmons |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1487815684 PECOS PAC ID: 0749454171 Enrollment ID: I20111122000321 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Reginald B Richardson |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1104083427 PECOS PAC ID: 1658485966 Enrollment ID: I20120213000415 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Millicent B Brown |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1285863852 PECOS PAC ID: 1456508837 Enrollment ID: I20120821000498 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Tori N Simmons Lewis |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1891007639 PECOS PAC ID: 8426296617 Enrollment ID: I20130529000883 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Lana N Nealand |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1598109902 PECOS PAC ID: 7416196985 Enrollment ID: I20130625000585 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Joel Daniel Kelly |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1669632881 PECOS PAC ID: 4688866437 Enrollment ID: I20131127001230 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Tamika Gooden |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1487968780 PECOS PAC ID: 6103053145 Enrollment ID: I20131218001003 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Devin Grant |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1770838187 PECOS PAC ID: 1052628393 Enrollment ID: I20150917002937 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Helen D Bragg |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1902270499 PECOS PAC ID: 0840597332 Enrollment ID: I20160608000001 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Zelda Fleming |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1376068320 PECOS PAC ID: 1951676345 Enrollment ID: I20171011001826 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Jessica Lynn Wilczek |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1609236082 PECOS PAC ID: 7911252440 Enrollment ID: I20180625000077 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | John K Throckmorton |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1114983723 PECOS PAC ID: 0941207658 Enrollment ID: I20180710002646 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Neil Younce |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1164833554 PECOS PAC ID: 7315216306 Enrollment ID: I20190911000476 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Erin Marie Younce |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1174963789 PECOS PAC ID: 6800185281 Enrollment ID: I20191203002219 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Emad Youssef |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1558747634 PECOS PAC ID: 8325394943 Enrollment ID: I20191219003019 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Melissa Gaffney |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1699968206 PECOS PAC ID: 6507958238 Enrollment ID: I20210202000305 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Jatinder Jit Kaur |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1629745153 PECOS PAC ID: 3779972336 Enrollment ID: I20211119002052 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Sara Naguib |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1891177713 PECOS PAC ID: 1052652880 Enrollment ID: I20220601000124 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Brandon Lee |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1962909366 PECOS PAC ID: 8729337993 Enrollment ID: I20230906003198 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Charles Jonathan Lyerly |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1104443100 PECOS PAC ID: 3779947908 Enrollment ID: I20230906004155 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Daniel R Wright |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1437535267 PECOS PAC ID: 8022380542 Enrollment ID: I20230919003348 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Provider Name | Elizabeth Marie Cassandra |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1942977400 PECOS PAC ID: 5799173993 Enrollment ID: I20231107002570 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gooden Mobile Pod Nc Pllc 12910 Shelbyville Rd Ste 300, Louisville, KY 40243-2404 Ph: (502) 244-2441 | Gooden Mobile Pod Nc Pllc 311 Mcfadyen Dr, Fayetteville, NC 28314 Ph: (502) 244-2441 |
News Archive
AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"Nearly three years into a Medicaid privatization program former [Florida] Gov. Jeb Bush said could be a national model, state officials say they do not have crucial data to measure the program's effectiveness, including how many patients' treatments and prescriptions have been approved or denied," the AP/Miami Herald reports.
Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts.
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist.
A West African community has joined the network of community-based treatment support programs that form Bristol-Myers Squibb's real world field test of how HIV/AIDS treatment can best be combined with community-based care in some of the poorest and most remote areas of sub-Saharan Africa.
› Verified 6 days ago
Terrill F Brown, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1738 Metromedical Dr, Fayetteville, NC 28304 Phone: 910-484-4191 Fax: 910-484-5546 | |
Mark T Eaton, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1738 Metromedical Dr, Fayetteville, NC 28304 Phone: 910-484-4191 Fax: 910-484-5546 | |
Daniel E Laut, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1738 Metromedical Dr, Fayetteville, NC 28304 Phone: 910-484-4191 Fax: 910-484-5546 | |
Cape Fear Podiatry Associates, Pa Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1738 Metromedical Dr, Fayetteville, NC 28304 Phone: 910-484-4191 Fax: 910-484-5546 | |
Dr. George John Demetri Jr., DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 7300 S Raeford Rd, Fayetteville, NC 28304 Phone: 910-488-2120 | |
Dr. Denise Crystal Thomas, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1738 Metromedical Dr, Fayetteville, NC 28304 Phone: 910-484-4191 Fax: 910-484-5546 |